Response to Comment on "Fluocinolone Acetonide Intravitreal Implant for Treating Recurrent Non-Infectious Uveitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal"
Pharmacoeconomics
.
2020 Jun;38(6):649-651.
doi: 10.1007/s40273-020-00900-y.
Authors
Xavier G L V Pouwels
1
,
Svenja Petersohn
1
,
Vanesa Huertas Carrera
2
,
Alastair K Denniston
3
4
,
Annette Chalker
2
,
Heike Raatz
2
5
,
Nigel Armstrong
2
,
Willem Witlox
1
,
Gill Worthy
2
,
Caro Noake
2
,
Rob Riemsma
6
,
Jos Kleijnen
2
7
,
Manuela A Joore
1
7
Affiliations
1
Maastricht University Medical Centre+, Maastricht, The Netherlands.
2
Kleijnen Systematic Reviews Ltd, York, UK.
3
University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.
4
University of Birmingham, Birmingham, UK.
5
European Centre of Pharmaceutical Medicine, Basel University, Basel, Switzerland.
6
Kleijnen Systematic Reviews Ltd, York, UK. rob.riemsma@systematic-reviews.co.uk.
7
Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, The Netherlands.
PMID:
32249398
DOI:
10.1007/s40273-020-00900-y
No abstract available
Publication types
Letter
Research Support, Non-U.S. Gov't
Comment
MeSH terms
Fluocinolone Acetonide*
Humans
Uveitis*
Substances
Fluocinolone Acetonide
Grants and funding
16/119/02/DH_/Department of Health/United Kingdom